LCM
EGRX

Landscape Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Landscape Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,723
Closed -$341K – 782
2017
Q3 		$341K Buy
+5,723
New +$346K 0.03% 377

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Landscape Capital Management's EGRX Position: Q4 2017 in Review

Landscape Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2017, closing a stake of 5,723 shares — an estimated $341K sold.

Landscape Capital Management first reported a position in EGRX in Q3 2017 and held it in 1 quarter. The position peaked at $341K in Q3 2017. 170 funds tracked by Wall St. Rank hold EGRX as of Q4 2017.

  • Landscape Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Landscape Capital Management sold 5,723 Eagle Pharmaceuticals, Inc. shares in Q4 2017, an estimated $341K.
  • Landscape Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
  • Landscape Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $341K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2017.

Based on Landscape Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.